posted
This may hurt. Q1 report from the Adolor website:
EXTON, Pa.--(BUSINESS WIRE)--May 3, 2007--Adolor Corporation (Nasdaq:ADLR) today reported financial results for the three months ended March 31, 2007.
For the three months ended March 31, 2007, the company reported a net loss of $13.2 million or $(0.29) per basic and diluted share, compared to a net loss of $17.4 million or $(0.42) per basic and diluted share for the same period in 2006.
Contract revenues for the quarter ended March 31, 2007 were $1.8 million, compared to $2.6 million in the same period of 2006. This decrease was primarily due to a decrease in co-promotion revenues of $0.7 million from our Arixtra(R) co-promotion agreement with Glaxo, which expired in 2006.
Research and development expenses in the first quarter of 2007 were $11.6 million, compared to $14.6 million for the same period in 2006. This decrease was principally related to decreased expenses relating to our Entererg(R) (alvimopan) program and sterile lidocaine patch program which was discontinued in 2006. These decreases were partially offset by the increase in expenses related to our Delta program.
Marketing, general and administrative expenses decreased to $5.8 million in the first quarter of 2007 from $7.5 million in the first quarter of 2006, as a result of decreased personnel expenses, including stock-based compensation expenses associated with Statement of Financial Accounting Standards 123R, combined with lower marketing and sales expenses.
As of March 31, 2007, the Company had $169.3 million in cash, cash equivalents and short-term investments.
Posts: 124 | Registered: Oct 2006
| IP: Logged |
posted
IMO Patience will soon pay off with this one. Been flatlined for almost a month now. Its ever so slowly creeping its way back up. Stick with it.
Posts: 137 | Registered: Jan 2007
| IP: Logged |
posted
First time I'm in on a stock I found on the allstocks messageboards. Very interesting find.. it's not often you find a company like this trading near cash value per share. Good luck to those who are in.. looks like something's going to happen soon!
Posts: 31 | Registered: Oct 2006
| IP: Logged |
posted
All those form 4s seem to be conversion of options. I don't think any were actual open market purchases.
Posts: 5508 | From: Southeastern PA | Registered: Jan 2006
| IP: Logged |
GlaxoSmithKline, Adolor Get FDA Request for More Data on Halted Constipation Treatment Studies
NEW YORK (AP) -- British drug maker GlaxoSmithKline PLC and biotech drug maker Adolor Corp. said Monday that the Food and Drug Administration requested safety data on their experimental constipation treatment Entereg.
The agency requested the information in connection with a Nov. 6, 2006 "approvable" letter, which the FDA issues when a drug application is in order but more information is needed for a full approval. GlaxoSmithKline and Adolor, however, suspended studies of the drug in April after safety studies revealed patients taking the drug were more prone to benign and cancerous lesions, fractures and cardiovascular events including heart attack.
The companies also withdrew their marketing application for the drug, and the FDA placed a clinical hold on the drug. GlaxoSmithKline and Adolor currently have no ongoing studies on the drug. Entereg was Adolor's lead drug candidate.
The FDA wants final results from a mid-stage study on the drug in cancer pain patients with opioid-induced bowel dysfunction, data from two-year carcinogenicity studies in rats and mice, and safety data from another discontinued study, the companies said.
Adolor said it expects to submit all the data to FDA by the third quarter, at which time GlaxoSmithKline plans to update their development plans for the drug.
Shares of Adolor rose 25 cents, or 6.7 percent, to $4 in premarket trading, after closing Friday at $3.75. GlaxoSmithKline's American Depositary Shares added 9 cents to $51.66 in premarket trading, having finished Friday at $51.57.
Posts: 31 | Registered: Oct 2006
| IP: Logged |
(RealTrader) *Adolor Corp President & CEO Dougherty Michael R Purchased 25,000 Shares at $1.59 on 11/20/2008 - [ADLR] *Adolor Corp President & CEO Dougherty Michael R Purchased 25,000 Shares at $1.59 on 11/20/2008 - [ADLR]
-------------------- Let's Go METS!!! Posts: 3317 | From: CT | Registered: Dec 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
